{"id":522821,"date":"2021-08-04T07:04:25","date_gmt":"2021-08-04T11:04:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-reports-record-second-quarter-2021-financial-results-increasing-full-year-2021-net-sales-and-adjusted-ebitda-guidance\/"},"modified":"2021-08-04T07:04:25","modified_gmt":"2021-08-04T11:04:25","slug":"horizon-therapeutics-plc-reports-record-second-quarter-2021-financial-results-increasing-full-year-2021-net-sales-and-adjusted-ebitda-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/horizon-therapeutics-plc-reports-record-second-quarter-2021-financial-results-increasing-full-year-2021-net-sales-and-adjusted-ebitda-guidance\/","title":{"rendered":"Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance"},"content":{"rendered":"

<\/p>\n

Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance <\/b><\/p>\n

— Record Second-Quarter 2021 Net Sales of $832.5 Million Increased 80 Percent; Second-Quarter 2021 GAAP Net Income of $158.1 Million; Adjusted EBITDA of $366.9 Million —<\/i><\/p>\n

— Record TEPEZZA\u00ae (teprotumumab-trbw) Second-Quarter 2021 Net Sales of $453.3 Million Driven by Strong Demand and Relaunch Execution; Increasing Full-Year 2021 Net Sales Guidance to Greater Than $1.550 Billion and Expect Fourth-Quarter Year-Over-Year Growth of More Than 50 Percent —<\/i><\/p>\n

— Record KRYSTEXXA\u00ae (pegloticase injection) Second-Quarter 2021 Net Sales of $130.3 Million Increased 73 Percent; KRYSTEXXA Plus Immunomodulation Now at More Than 40 Percent —<\/i><\/p>\n

— Increasing Full-Year 2021 Net Sales Guidance to $3.025 Billion to $3.125 Billion, Representing 40 Percent Growth at the Midpoint; Increasing Full-Year 2021 Adjusted EBITDA Guidance to $1.26 Billion to $1.30 Billion, Representing 28 Percent Growth at the Midpoint —<\/i><\/p>\n

— Advancing Pipeline to Drive Long-Term Growth; Entered into Agreement with Arrowhead to Develop a Next-Generation Gout Medicine; Initiated Three Clinical Trials —<\/i><\/p>\n

— Acquired Biologics Drug Product Manufacturing Facility to Support Growth of On-Market Medicines and Development-Stage Biologics —<\/i><\/p>\n

— Hosting Virtual R&D Day on Sept. 29, 2021 —<\/i><\/p>\n

DUBLIN–(BUSINESS WIRE<\/a>)–
\nHorizon Therapeutics plc (Nasdaq: HZNP) today announced record second-quarter 2021 financial results and increased both its full-year 2021 net sales and adjusted EBITDA guidance.\n<\/p>\n

\n\u201cDriving our record second-quarter performance was our highly successful TEPEZZA relaunch, which allowed Thyroid Eye Disease patients to rapidly access therapy and resulted in an increase in our full-year expectations,\u201d said Tim Walbert, chairman, president and chief executive officer, Horizon. \u201cOur increased full-year net sales and adjusted EBITDA guidance represents strong double-digit year-over-year growth driven by TEPEZZA, KRYSTEXXA and our other rare disease medicines, where we are seeing continued strong underlying demand given the significant benefits our medicines provide to patients. We also initiated three clinical trials and acquired a biologics drug product manufacturing facility to support our strategy to maximize our key growth drivers, expand our pipeline and build a global presence. Horizon remains one of the fastest-growing biotechnology companies, underscoring our commitment to generate value for patients and our shareholders.\u201d\n<\/p>\n

Financial Highlights<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n
(in millions except for per share amounts and percentages)<\/td>\nQ2 21<\/b><\/td>\n\nQ2 20<\/b><\/td>\n\n%
Change<\/b><\/td>\n		\nYTD 21<\/b><\/td>\n\nYTD 20<\/b><\/td>\n\n%
Change<\/b><\/td>\n<\/tr>\n
\n\n\n\n\n\n\n\n\n\n\n\n\u00a0<\/td>\n<\/tr>\n
Net sales<\/td>\n\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n832.5\n<\/p>\n<\/td>\n

\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n462.8\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n\n

\n80\n<\/p>\n<\/td>\n

\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n1,175.0\n<\/p>\n<\/td>\n

\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n818.7\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n\n

\n44\n<\/p>\n<\/td>\n<\/tr>\n

Net income (loss)<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n158.1\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(80.0\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

\n\n

\n298\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n34.8\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(93.6\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

\n\n

\n137\n<\/p>\n<\/td>\n<\/tr>\n

Non-GAAP net income<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n381.4\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n83.8\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n\n

\n355\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n388.8\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n167.0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n\n

\n133\n<\/p>\n<\/td>\n<\/tr>\n

Adjusted EBITDA<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n366.9\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n190.7\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n\n

\n92\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n412.7\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n297.9\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n\n

\n39\n<\/p>\n<\/td>\n<\/tr>\n

\n\n\n\n\n\n\n\n\n\n\n\n\u00a0<\/td>\n<\/tr>\n
Earnings (Loss) per share – diluted<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.67\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(0.42\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

\n\n

\n261\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.15\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(0.49\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

\n\n

\n131\n<\/p>\n<\/td>\n<\/tr>\n

Non-GAAP earnings per share – diluted<\/td>\n\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1.62\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.40\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n\n

\n305\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1.66\n<\/p>\n<\/td>\n

\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n0.80\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n\n

\n108\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Second Quarter and Recent Company Highlights <\/b><\/p>\n